The following is a summary of Sakaguchi Y. et. al. which discusses types of erythropoitin-stimulating agents and mortality among patients undergoing hemodialysis.
- About
- Events
- Resource Center
- Community Corners
NephU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI) - committed supporters of the Kidney Health Community. The information provided through NephU is intended for the educational benefit of health care professionals and others who support care for those with kidney disease and other related conditions. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing NephU 's educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by NephU. Some of the contributors may be paid consultants of OPDC and/or OAPI.
©2021 Otsuka Pharmaceutical Development & Commercialization, Inc. All rights reserved.May 2020 MRC2.CORP.X.04767 - Events
